# Stop failing trials earlier with pre-registered aggressive futility rules

Source: https://onco.cc/ideas/idea-tr1-aggressive-futility-boundaries/  
OnCo record `idea-tr1-aggressive-futility-boundaries` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Large phase 3 trials often continue for years after interim data show the drug is unlikely to work. Pre-registering futility boundaries at 30 to 50 percent of the information, judged by independent committees and reported publicly, would stop them earlier, sparing patients and freeing money for better ideas.

## Summary

Phase 3 protocols include non-binding but pre-registered futility boundaries at 30-50 percent information (predictive probability of success below a threshold), evaluated by independent monitoring committees, with public reporting of the interim decision. Sponsors commit to the rule in the registry entry, reducing the temptation to continue for commercial reasons.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Trials with pre-registered aggressive futility rules will stop negative studies a median of 12 months earlier and expose 30 percent fewer patients to ineffective experimental arms, with a negligible increase in falsely abandoned effective drugs.
- Rationale: Retrospective analyses of negative phase 3 trials show most would have met conventional futility criteria at interim, yet sponsors often lack pre-specified rules or set them conservatively.
- Proposed test: Simulate aggressive futility rules on completed negative phase 3 trials with interim data available and quantify time and patients saved versus false stops of positive trials.
- Maturity: speculative
- Actor: industry

## Sources

- Bottleneck evidence (Trial design, endpoints and cost): Davis et al., Availability of evidence of benefits on survival and quality of life of cancer drugs approved by EMA 2009-13 (BMJ 2017): https://doi.org/10.1136/bmj.j4530

## Connected records

- collections: [ClinicalTrials.gov](https://onco.cc/collections/clinicaltrials-gov/)
- bottlenecks: [Failures are hidden](https://onco.cc/bottlenecks/b-negative-results/), [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/)
- key papers: [Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13](https://onco.cc/key-papers/paper-davis-bmj/)

---
JSON: https://onco.cc/api/v1/entities/idea-tr1-aggressive-futility-boundaries.json